Baseline characteristics hps
This presentation is the property of its rightful owner.
Sponsored Links
1 / 5

Baseline Characteristics: HPS PowerPoint PPT Presentation


  • 48 Views
  • Uploaded on
  • Presentation posted in: General

Baseline Characteristics: HPS. Heart Protection Study Collaborative Group. Lancet 2003;361:2005–2016. HPS: Mean SE Differences in Lipids (Simvastatin – Placebo). Heart Protection Study Collaborative Group. Lancet 2003;361:2005–2016. Risk ratio and 95% CI. 0.4. 0.6. 0.8. 1.0. 1.2.

Download Presentation

Baseline Characteristics: HPS

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Baseline characteristics hps

Baseline Characteristics: HPS

Heart Protection Study Collaborative Group. Lancet 2003;361:2005–2016.


Hps mean se differences in lipids simvastatin placebo

HPS: MeanSE Differences in Lipids(Simvastatin – Placebo)

Heart Protection Study Collaborative Group. Lancet 2003;361:2005–2016.


Hps major vascular events by prior diabetes

Risk ratio and 95% CI

0.4

0.6

0.8

1.0

1.2

1.4

HPS: Major Vascular Events by Prior Diabetes

STATIN Better

PLACEBO Better

27% reduction (15–38)p<0.0001

24% reduction (6–39)p=0.01

17% reduction (3–30)p=0.02

22% reduction (13–30)p<0.0001

Heart Protection Study Collaborative Group. Lancet 2003;361:2005–2016.

Reprinted with permission from Elsevier Science.


Hps major vascular events by year in patients with diabetes

0

1

2

3

4

5

6

–1(6)

13(8)

34(9)

47(10)

51(15)

58(48)

Benefit/1000 (SE)

HPS: Major Vascular Events by Year in Patients with Diabetes

Logrank p<0.00001

Placebo

Patients with Events (%)

Simvastatin

Years of Follow-up

Heart Protection Study Collaborative Group. Lancet 2003;361:2005–2016.

Reprinted with permission from Elsevier Science.


Hps major vascular events by ldl c and prior diabetes

0.4

0.6

0.8

1.0

1.2

1.4

HPS: Major Vascular Events by LDL-C and Prior Diabetes

Risk ratio and 95% CI

STATIN Better

PLACEBO Better

27% reduction (13–40)p=0.0007

Heart Protection Study Collaborative Group. Lancet 2003;361:2005–2016.

Reprinted with permission from Elsevier Science.


  • Login